Dry powder formulations for inhalation
A respirable dry powder can include acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μm to about 10 μm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as an amino acid (e.g., Leucine), in an amount ranging from about 0.1% (w/w) to about 40% (w/w) of the particles.
1. A dry powder composition comprising dry particles that comprise acetylsalicylic acid or a pharmaceutically acceptable salt thereof, wherein the dry particles have a mass median aerodynamic diameter (MMAD) within a range of about 0.5 μm to about 10 μm, wherein the composition comprises one or more amino acids in an amount ranging from about 5% (w/w) to about 15% (w/w) of the composition, and wherein the dry powder composition is suitable for delivery to a subject by inhalation, and wherein the MMAD of the dry particles varies less than about 10% after the dry powder composition is stored at 30° C. at 65% relative humidity for about 4 weeks, the MMAD of the dry particles varies less than about 10% after the dry powder composition is stored at 50° C. at 75% relative humidity for about 2 weeks, or the MMAD of the dry particles varies less than about 10% after the dry powder composition is stored at 50° C. for about 5 days.
2. The dry powder composition according to claim 1 , wherein the one or more amino acids is Leucine.
3. The dry powder composition according to claim 1 , wherein the one or more amino acids does not comprise Leucine.
4. The dry powder composition according to claim 1 , wherein acetylsalicylic acid or a pharmaceutically acceptable salt thereof is in an amount greater than 50% (w/w) of the composition.
5. The dry powder composition according to claim 1 , wherein the MMAD ranges from about 2.0 to about 5.0 μm.
6. The dry powder composition according to claim 1 , further comprising clopidogrel.
7. A drug delivery system effective to reduce the risk of a thromboembolic event or treat thrombosis, wherein the system comprises the dry powder composition of claim 1 .
8. The drug delivery system according to claim 7 , further comprising clopidogrel or at least one other excipient selected from the group consisting of sodium lauryl sulfate, lactose, starch, cellulose, sodium citrate, maltodextrin and mannitol.
9. The drug delivery system according to claim 7 , further comprising clopidogrel.
10. A method of treating reducing the risk of thrombosis or a thromboembolic event in a subject, the method comprising administering to a subject in need thereof a therapeutically effective dose of the dry powder of claim 1 .
11. The method according to claim 10 , wherein the thromboembolic event comprises at least one of unstable angina or a myocardial infarction or a transient ischemic attack or a stroke.
12. The method according to claim 11 , wherein the thromboembolic event is treated within about 5 minutes, or within about 10 minutes, of onset of the ischemic event.